Gilead pays $40m to settle allegations that it delayed work on an improved HIV drug to maximise profits from an older drug. Dyer O. BMJ 2024;385:q1285.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dyer O. Gilead pays $40m to settle allegations that it delayed work on an improved HIV drug to maximise profits from an older drug. BMJ 2024;385:q1285.
PMID: 38862153